drugset / Trial / NCT02151994

Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.

NCT02151994

Phase 1 Completed 124 enrolled Bial - Portela C S.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to to assess the safety and tolerability of BIA 5 1058 after single and multiple oral doses

Timeline

Start
2011-03
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject zamicastat Small molecule 5 mg Oral
Subject zamicastat Small molecule 25 mg Oral
Subject zamicastat Small molecule 50 mg Oral
Subject zamicastat Small molecule 100 mg Oral
Subject zamicastat Small molecule 400 mg Oral